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Abstract
Background: The stepped wedge (SW) cluster randomized controlled trial (CRCT) design is being used with
increasing frequency. However, there is limited published research on the quality of reporting of SW-CRCTs. We
address this issue by conducting a literature review.
Methods: Medline, Ovid, Web of Knowledge, the Cochrane Library, PsycINFO, the ISRCTN registry, and ClinicalTrials.
gov were searched to identify investigations employing the SW-CRCT design up to February 2015. For each included
completed study, information was extracted on a selection of criteria, based on the CONSORT extension to CRCTs, to
assess the quality of reporting.
Results: A total of 123 studies were included in our review, of which 39 were completed trial reports. The standard of
reporting of SW-CRCTs varied in quality. The percentage of trials reporting each criterion varied to as low as 15.4%, with
a median of 66.7%.
Conclusions: There is much room for improvement in the quality of reporting of SW-CRCTs. This is consistent with
recent findings for CRCTs. A CONSORT extension for SW-CRCTs is warranted to standardize the reporting of SW-CRCTs.
Keywords: Cluster randomized controlled trial, Reporting quality, Review, Stepped wedge
Background
The randomized controlled trial (RCT) has long been
considered the ‘gold standard’ for determining the effect-
iveness of an experimental intervention compared with a
contemporary control [1]. Consequently, much research
has been conducted to determine how to best design,
analyze, and report such trials [1–4]. Since the 1980s, a
subset of possible RCT designs has been given substan-
tial attention; the cluster randomized controlled trial
(CRCT) design [5]. As defined by Hayes and Moulton in
2009 [6], in a CRCT, ‘groups [are] randomly allocated to
treatment arms. These groups are referred to as clusters
[…] Examples of clusters include schools, communities,
factories, hospitals, or medical practices, but there are
many other possible choices.’ In particular, such designs
have been employed when it is inappropriate or
impossible to use individual-level randomization, or
when the group effects are of primary interest.
One possible CRCT design is the stepped wedge (SW);
first proposed by Cook and Campbell [7], and first
utilized in the Gambia Hepatitis Study [8]. In the
SW-CRCT approach, the intervention is introduced over
a number of time periods, with the order in which each
cluster begins receiving the intervention determined at
random. In the classical form of the design, all clusters
begin in the control condition, and all receive the inter-
vention by the completion of the trial, with all clusters
actively taking part in the trial at each time period.
Moreover, once a cluster switches to the intervention, it
does not switch back to the control. However, whilst this
latter feature remains common to all proposed
SW-CRCT designs, recently numerous extensions have
been proposed that, for example, allow some clusters to
begin in the intervention, end in the control condition,
or only actively take part in certain time periods [9].* Correspondence: mjg211@cam.ac.ukMRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge
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In addition, there are several variations of the
SW-CRCT according to the chosen method of data
acquisition. For example, some trials may involve cross-
sectional examination of a population, potentially accru-
ing measurements from an entirely different set of
subjects in each time period [10]. At the other end of
the scale, they could involve gathering repeated
measurements from a single cohort [11].
Indeed, much has been written in recent years
about SW-CRCTs; from papers recommending how to
design and analyze these trials, to reports on com-
pleted SW trials. Methodology [10–14] and software
[15] now exists to determine required sample sizes
and the optimal timings of the steps in a stepped
wedge design have been ascertained [16, 17], whilst,
as discussed, extensions to the standard design to
allow for multiple levels of clustering or ‘incomplete
block’ designs have also been presented [9]. Numer-
ous papers have discussed when the design is more
efficient, or preferential on alternate grounds, such as
ethical or logistical grounds, to the parallel group
CRCT [10, 18–27], whilst there have also been rec-
ommendations on how to analyze and report trials
employing the SW-CRCT design [28]. Overviews of
some of the benefits and limitations of SW-CRCTs
can be found in the studies of de Hoop et al. [29],
Hargreaves et al. [30], and Prost et al. [31].
However, little research has been conducted to deter-
mine the reporting quality of SW-CRCTs. The first two
systematic reviews assessing SW-CRCTs [32, 33] were
performed when few trials had used the design. Thus,
they were unable to come to any strong conclusions
about the quality of reporting; however, they did suggest
that there was much room for improvement. Two more
recently completed reviews [34] did give some consider-
ation to the standard of reporting of completed
SW-CRCTs. However, they only assessed a small selec-
tion of reporting quality indicators, primarily focusing
on the employed analysis methods, and on trial reports
published from 2010 to 2014. Similarly, Martin et al.
[35] did assess reporting standards, but concentrated on
nine indicators relating to sample size calculations.
Finally, a 2016 review focused on the available statistical
methodology for designing and analyzing SW-CRCTs
that have been used to date [36]. Consequently, identifi-
cation of any substantial reporting failures, unrelated to
sample size calculation or trial analysis, remains an
important step to be undertaken. Specifically, little is
known about how well trials have been introduced, the
results presented, or the trials discussed thereafter. In
this work, we address this issue by conducting a litera-
ture review on SW-CRCTs with no limits on the calendar
time, with 43 indicators of the quality of reporting consid-
ered, drawn from across the CONSORT statement for
CRCTs [37, 38], allowing us to assess broadly the standard
of reporting of conducted SW-CRCTs. In addition, we are
able to provide a detailed analysis of numerous design fea-
tures of SW-CRCTs.
Methods
A protocol of the literature review is provided as
Additional file 1. A completed PRISMA checklist [39] is
available as Additional file 2 and a flow diagram for the
review appears in Fig. 1.
Literature search strategy
PubMed (including Medline), Ovid (including Embase),
Web of Knowledge, PsycINFO, the Cochrane Library, the
ISRCTN registry and ClinicalTrials.gov were searched on
24 February 2015. No publication date restrictions were
applied to the search. In addition, reference lists of the
studies included in the final analysis were checked, along
with those of several other relevant papers.
Based on the protocol of Mdege et al. [33], the follow-
ing phrases were used: ‘stepped wedge’, ‘step wedge’,
‘experimentally staged introduction’, ‘delayed interven-
tion’, ‘one directional crossover design’, and the 15 possible
combinations of ‘incremental’/‘phased’/‘staggered’/‘step
wise’/‘delayed’ and ‘recruitment’/‘introduction’/‘implemen-
tation’. Explicitly, these terms were entered for each
database as follows:
 Pubmed. In the Advanced Search Builder, ‘All Fields’
was set to each of the 20 search terms in turn, e.g.
‘stepped wedge’. Results were downloaded as a.txt
file.
 Ovid. Embase 1974 to 2015 Week 6 was included.
In the Advanced Search tab, each of the 20 search
terms were entered in turn as a keyword, e.g. ‘stepped
wedge’. Results were downloaded as a.txt file.
 PsycINFO. In the Advanced Search tab, ‘Any Field’
was set to each of the 20 search terms in turn, e.g.
‘stepped wedge’. Results were downloaded as a.ris file.
 Cochrane Library. In the Search tab, ‘Search All
Text’ was set to each of the 20 search terms in
turn, e.g. ‘stepped wedge’. Results were downloaded
as a.txt file.
 Web of Knowledge. In a Basic Search, ‘Topic’ was set
to each of the 20 search terms in turn, e.g. ‘stepped
wedge’. ‘TIMESPAN’ was set to ‘All years’. Results
were downloaded as a.txt file.
 ISRCTN registry. In an Advanced Search, ‘Text
search’ was set to each of the 20 search terms in
turn, e.g. ‘stepped wedge’. Results were copied by
hand (title of study, registry number, primary
contact) into a.csv file.
 ClinicalTrials.gov. In an Advanced Search, ‘Search
Terms’ was set to each of the 20 search terms in
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turn, e.g. ‘stepped wedge’. Results were downloaded
as a.csv file.
Following this, identified records were merged into
one.csv file for analysis using R v. 3.1.3 [40]. For further
information, see Additional file 1.
Study inclusion and exclusion criteria
Studies were included if they reported an original trial
that used, or planned to use, a SW-CRCT design. Specif-
ically, we here define a SW-CRCT to be any trial meet-
ing the following criteria:
 Cluster-level allocation was utilized to compare
experimental interventions with controls.
 Data were gathered in at least three time periods on
at least two clusters.
 Each cluster begins in a control condition and changes
from this control to an experimental intervention
exactly once during the study, and then remains on
this experimental intervention.
 The time point at which clusters change from
control states to experimental ones is randomized,
and not identical for all clusters.
 Data are gathered for every included cluster in every
time period.
 An analysis is performed and reported on at least one
primary outcome measure, for each experimental
intervention, incorporating data from a time period in
which all clusters received the intervention.
Note, therefore, that trials where clusters were not
randomly allocated a time point for initiation of the
experimental intervention were excluded, as were ‘be-
fore-and-after’ studies in which the time of switching to
experimental interventions was equal for all clusters.
Given our focus on CRCTs, trials where individual-level
randomization was used were excluded. We also allow
studies in which more than one experimental interven-
tion is explored (being compared with identical or differ-
ing controls), but only if the clusters used to analyze
each experimental intervention are entirely separate; we
Fig. 1 Flow diagram of records through the literature review. 123 studies were ultimately included in our review. PG-CRCT, parallel group clus-
tered randomized controlled trial; SW, stepped wedge
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do not consider cases in which clusters switch between
experimental interventions. Additionally, duplicate or
secondary analysis publications for the same study were
counted as one study, although data on the general char-
acteristics of the design used (i.e. not the indicators of
reporting standards) may have been extracted from
several sources.
Further, we exclude trials in which some clusters were
only offered an experimental intervention after the
completion of the trial or data analysis, or where some
clusters begin the trial on the experimental intervention.
This is to focus on what many would consider the
classical SW-CRCT design. It also ensures that parallel
group CRCTs with baseline periods, or more than one
follow-up period, are omitted without the need for
additional inclusion criteria. Finally, our requirement
that data must be gathered for every included cluster, in
every time period, prevents the inclusion of ‘incomplete
block’ SW-CRCTs [9]. Similarly, this allows us to
concentrate on the reporting of the classical SW-CRCT
design, and core features that should be present in this
instance. It is probable that several additional reporting
features should be present for more specialized SW-
CRCT designs. Note, therefore, that in what follows,
when we refer to SW-CRCTs, we mean what we have
described here as the classical SW-CRCT, as prescribed
by these criteria.
Selection of studies for inclusion in the review
MJG screened the titles and abstracts of all records
retrieved from the literature search to identify all poten-
tially relevant full articles to be assessed for potential
inclusion in the review. The full articles were then evalu-
ated according to the pre-specified inclusion and exclusion
criteria; being classified as included, excluded, or having
insufficient information. For those with insufficient infor-
mation to make a decision, the corresponding authors
were contacted for further details (this, in particular,
included studies where only abstracts or protocol
summaries were available).
Data extraction and analysis
Data were extracted from all included studies by MJG
according to a pre-specified set of questions (see
Additional file 1). The set included questions on study
identifiers (such as lead author), the research area (such
as disease or domain, setting and country), the motivations
for using a SW-CRCT design, the general characteristics of
the SW-CRCT design (such as number of clusters) and the
data analysis method.
Additionally, for the included full trial reports, data were
extracted on an additional 43 questions to assess the qual-
ity of reporting of SW-CRCTs (see Additional file 1 and
Table 3). These criteria were selected according to those
previously used [33], in addition to several based on the
CONSORT extension to CRCTs [37, 38]. They were
designed to assess the reporting quality of SW-CRCTs
across all sections of the CONSORT statement. Whenever
conclusions were unclear, final decisions were made
through discussion with an additional author (JMSW or
APM). The limitations of this record selection and data
extraction procedure are discussed later in this article.
The reporting quality of the full trial reports was
further examined by evaluating performance on the
subset of the 43 assessed indicators listed on the
CONSORT extensions to CRCTs; since the lack of an
available CONSORT extension to SW-CRCTs makes
this, at present, the best available advice for publication
of SW-CRCTs, and it would therefore be hoped that
trials would adhere to its guidance. Likewise, the quality
of reporting was further graded on a subset of 10 of the
43 indicators chosen by the authors as key indicators.
Additional file 1 provides further information on how
these were chosen. Briefly, a group decision was made
after discussions to choose the criteria that would (a)
ease the identification of the trial as a SW-CRCT and
justify its use, (b) allow the key design features of the
utilized SW-CRCT to be determined and justified, and
(c) determine that the primary results of the trial were
soundly reported.
Moreover, as part of our review, data were also
extracted, for each included full trial report, on whether
a significant result was found for any of the trials pri-
mary endpoints. Within the literature, one of the pri-
mary reasons cited for using the SW-CRCT design is an
inherent belief that the intervention will be effective;
helping explain the desire to eventually implement it in
all clusters. However, this may not always be the case.
We further categorize the data according to whether a
minimum clinically important difference for the primary
endpoints, for which a pre-specified power was to be
achieved by the trial, was specified. That is, we assess
whether a statistically significant result was ascertained
on a primary endpoint for which a minimum clinically
important difference had been provided. In this way, a
single trial could then contribute to both categories (spe-
cified vs. unspecified minimum clinically important
difference) if it evaluated performance on several
primary endpoints, but only offered a minimum clinic-
ally important difference for a subset of these.
The final accrued data from our review were then ana-
lyzed, and figures produced, using R v. 3.3.2 [40].
Results
Literature search
The flow of the records through the review process is
presented in Fig. 1. A total of 10,824 records were ini-
tially identified, of which 3104 were found to be
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duplicates. Title and abstract screening found 7248 to be
irrelevant, leaving 472 for full article assessment to
determine eligibility. Of these, 349 were found to be
ineligible. This left 123 studies (39 full trial reports and
84 trial registrations, protocols or conference reports)
meeting the eligibility criteria for inclusion in the review.
A spreadsheet containing the extracted information on
these studies is provided as Additional file 3. Note that
these 123 studies include all of those from the previously
conducted reviews [32–35, 41] that meet our chosen
inclusion criteria.
The where, when and why of SW-CRCTs
Table 1 depicts the research areas in which SW-CRCT de-
signs have been used, the countries in which the studies
were carried out, whether industry support was received
for the study, and the reasons given for utilization of a
SW-CRCT. In addition, Fig. 2 displays the cumulative
frequency of the publication year of each included study.
We observe that health-related research has over-
whelmingly accounted for the majority of identified
SW-CRCTs, with only a few examples of social and
educational studies. This, however, may be a conse-
quence of the databases used in our search. Nonetheless,
within the health-related trials, an extremely broad
selection of research domains can be observed, includ-
ing, for example, HIV [42], asthma [43], hand hygiene
[44], prostate cancer [45] and water contamination [46].
Moreover these trials have been conducted in a wide
array of countries across Europe, North and South
America, Asia and Africa, with the UK and USA
accounting for the most, 20 studies each.
For a large majority of studies, no industry support was
received (108/123, 87.8%). It can be seen that the design
has been used substantially more often in recent years,
with particularly notable spikes in trial registrations, pro-
tocols and conference presentations from 2010 to 2015.
Finally, the most common reason given for the use of
the SW-CRCT design was a desire for the intervention
to be made available to all clusters by the end of the
trial, on ethical or equity grounds (51/123, 41.5%). The
other commonly cited reasons included logistical or
practical constraints (43/123, 35.0%), methodological
considerations (relating, for example, to clusters acting
as their own controls, having a comparison group at
each time period, and the fact that it allows between-
and within-cluster analyses) (15/123, 12.2%) and the
ability to adjust for, or study the effect of, time (13/123,
10.6%). A large number of included studies did not state
a reason for the designs use (45/123, 36.6%).
Design characteristics of SW-CRCTs
Figure 3 and Table 2 together depict the general design
characteristics of the included studies; the number of
steps, number of clusters, time period between steps, the
design type, and the number of participants (where each
of these was obtainable) according to being a report (i.e.
one of the 39 included completed studies) or other
assessed record (i.e. one of the 84 included trial registra-
tions, protocols or conference reports). Note that for the
reports these figures are then the final attained values
for the trial, whereas for the other records they are the
planned values before trial commencement. Therefore, it
should be remembered that the values for the other
Table 1 Use of the SW-CRCT design (N = 123)
Frequency (%)
Area
Health 117 (95.1)
Education 3 (2.4)
Social 3 (2.4)
Country
USA 20 (16.3)
UK 20 (16.3)
Netherlands 15 (12.2)
African 15 (12.2)
Australasian 12 (9.8)
Asian 10 (8.1)
Canada 9 (7.3)
South or Central American 8 (6.5)
Other European 6 (4.9)
France 5 (4.1)
Multiple 3 (2.4)
Received industry support
Yes 6 (4.9)
No 108 (87.8)
Unclear 9 (7.3)
Stated reasons for use
Everyone receives 51 (41.5)
None stated 45 (36.6)
Logistical or practical 43 (35.0)
Methodological 15 (12.2)
Time effects 13 (10.6)
Other 10 (8.1)
Cluster-level randomization 9 (7.3)
Prevent contamination bias 8 (6.5)
Encourage participation 7 (5.7)
Incorporate randomization 6 (4.9)
Efficiency grounds 6 (4.9)
Social or political acceptability 3 (2.4)
Fine-tune intervention 3 (2.4)
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included records may not prove to be indicative of those
ultimately used in SW-CRCTs.
We observe that SW-CRCTs have been, or are being,
conducted with greatly different characteristics. The
number of steps has varied from 2 to 16, with an overall
median of 9, whilst the number of clusters has varied
from 2 to 252, with an overall median value of 20.5.
Furthermore, the median overall time period between
steps was 12 weeks, but has varied from a few weeks up
to 2 years. Finally, the total number of participants in
SW-CRCTs has typically varied from a few hundred to a
few thousand, with an overall median of 1200. However,
there were instances of trials that planned to recruit only
40, or as many as 256,700, participants.
Fig. 2 Use of the SW-CRCT design. The cumulative frequency of the designs use over time is displayed, according to the included reports and
other records (trial registrations, protocols, conference reports)
Fig. 3 Design characteristics of SW-CRCTs. (a) Number of clusters and (b) time period between steps of the included studies (where clear) is depicted,
according to whether the study record is either a completed report or other record type (trial registrations, protocols, conference reports).
For completed reports, the final true figures are used; for the other records, the planned amounts are employed. For the box plot of the time periods
between steps, 1 month was treated as 4 weeks and 1 year as 52 weeks. Notches are used to display the 95% confidence interval for the median, and
the boxplot widths are proportional to the square root of the number of records on which they are based
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To date, the majority of SW-CRCTs have been of the
continuous recruitment short exposure type (48/123,
39.0%) discussed for example in [41]; where, as the name
suggests, participants are continually recruited and ex-
posed for a short period before a measurement is made.
There have, however, also been a large number of open
(28/123, 22.8%) and closed cohort trials (29/123, 23.6%).
Quality of reporting
We assessed the quality of reporting of the 39 included
full study reports using our 43 selected criteria. Sum-
mary results for each criteria are presented in Table 3.
Details for each study can be found in Additional file 3.
Additionally, Fig. 4 depicts a scatter graph of the
percentage of the three sets of criteria met by each full
report against publication year.
We observe that the percentage of the trial reports
meeting each criteria varied from 15.4% to 100.0%, with
an overall median of 66.7%. The median performance
across the 10 key criteria was also 66.7%; however, it was
80.8% for those criteria listed on the CONSORT exten-
sion to CRCTs. Note that the Pearson correlation
between the individual trial performance on the overall
and CONSORT criteria was 0.97, between the overall
and key criteria was 0.80, and between the CONSORT
and key criteria was 0.69, to two decimal places.
Highlighting several figures, we see very few studies
that detailed why clustered allocation was used in their
trial (6/39, 15.4%). 35.9% (14/39) did not justify use of a
SW-CRCT design, and only 61.5% (24/39) provided a
flow diagram of any kind. 41.0% (16/39) of the studies
used an intention-to-treat analysis, and 48.7% (19/39) of
the studies did not adequately detail who was blinded to
the intervention.
From Fig. 4a we see that the quality of reporting of
each individual trial is generally poor, with one study
meeting 39.0% of the criteria. However, from the Loess
smoother [47], and its 95% confidence interval, there
does appear to be somewhat of an upward trend in the
reports’ percentage scores as we approach the present
day. Similar statements hold when assessing the criteria
listed on the CONSORT extension to CRCTs (Fig. 4b),
and also the 10 key criteria (Fig. 4c). Nonetheless,
there were, worryingly, still four studies published in
either 2014 or 2015 that met fewer than 60% of the
CONSORT criteria, and one study in 2014 meeting
40% of the key criteria.
Primary outcome measure results
Our analysis of the full trial reports utilizing SW-CRCT
designs revealed that when a minimum clinically import-
ant difference had been specified for a primary outcome
measure, or measures, 52.0% (13/25) of these studies did
not find a significant effect of the intervention. This is
perhaps surprising, given the aforementioned notion that
SW-CRCTs are commonly used when there is an
a-priori belief that the intervention will be effective. In
contrast, however, when no minimum clinically im-
portant difference was specified for a primary out-
come measure, or measures, 85.0% (17/20) of studies
found a significant effect.
Discussion
The SW-CRCT design has received substantial attention
over the last few years. In this work, we have addressed
some of the issues associated with it through a literature
review. Principally, we sought to discern the reporting
Table 2 Design features of SW-CRCTs
Reports
(N = 39) (%)
Others
(N = 84) (%)
All
(N = 123) (%)
Design type
Continuous recruitment
short exposure
13 (33.3) 35 (41.7) 48 (39.0)
Open cohort 12 (30.8) 16 (19.0) 28 (22.8)
Closed cohort 12 (30.8) 17 (20.2) 29 (23.6)
Other 1 (2.6) 3 (3.6) 4 (3.3)
Unclear 1 (2.6) 13 (15.5) 14 (11.4)
Steps
2 2 (5.1) 3 (3.6) 5 (4.1)
3 1 (2.6) 2 (2.4) 3 (2.4)
4 1 (2.6) 1 (1.2) 2 (1.6)
5 11 (28.2) 1 (1.2) 12 (9.8)
6 1 (2.6) 1 (1.2) 2 (1.6)
7 3 (7.7) 10 (11.9) 13 (10.6)
8 1 (2.6) 0 (0) 1 (0.8)
9 7 (17.9) 13 (15.5) 20 (16.3)
10 4 (10.3) 0 (0) 4 (3.3)
11 5 (12.8) 12 (14.3) 17 (13.8)
12 1 (2.6) 11 (13.1) 12 (9.8)
13 1 (2.6) 5 (6.0) 6 (4.9)
14 0 (0) 1 (1.2) 1 (0.8)
15 0 (0) 2 (2.4) 2 (1.6)
16 0 (0) 1 (1.2) 1 (0.8)
Unclear 1 (2.6) 21 (25.0) 22 (17.9)
Total number of
participants
Reports
(N = 36)
Others
(N = 72)
All
(N = 108)
Minimum 123.0 40.0 40.0
Q1 368.8 400.0 400.0
Median 1112.0 1200.0 1200.0
Q3 3264.8 6330.8 4000.0
Maximum 26456.0 256700.0 256700.0
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Table 3 Quality of reporting of SW-CRCTs (N = 39)
Heading/subheading Criterion Yes (%) 95% confidence interval (%)
Title and abstract Phrase ‘step wedge’ or ‘stepped wedge’ used 26 (66.7) (51.0, 79.4)
Phrase ‘randomized’ used 29 (74.4) (58.9, 85.4)
Introduction or methods Rationale for stepped wedge design given 25 (64.1) (48.4, 77.3)
Rationale for clustering given 6 (15.4) (7.2, 29.7)
Specific objectives of the trial given 39 (100.0) (91.0, 100.0)
Diagram of the design provided 26 (66.7) (51.0, 79.4)
Description of the trial design provided 36 (92.3) (79.7, 97.3)
Eligibility criteria for clusters provided 25 (64.1) (48.4, 77.3)
Eligibility criteria for individuals provided 34 (87.2) (73.3, 94.4)
Settings and locations where data collected
adequately described
39 (100.0) (91.0, 100.0)
Interventions adequately described 37 (94.9) (83.1, 98.6)
Completely defined primary outcomes 36 (92.3) (29.3, 59.0)
Completely defined secondary outcomes* 22 (95.7) (79.0, 99.2)
Justification for sample size provided 24 (61.5) (45.9, 75.1)
Use or non-use of intracluster correlation
coefficient or coefficient of variation stated
17 (43.6) (29.3, 59.0)
Type-I error rate used stated 22 (56.4) (41.0, 70.7)
Type-II error rate for design stated 23 (59.0) (43.4, 72.9)
Method of random allocation used 23 (59.0) (43.4, 72.9)
Type or randomization used 36 (92.3) (29.3, 59.0)
Allocation concealment mechanism used 12 (30.8) (18.6, 46.4)
Who implemented the randomization detailed 15 (38.5) (24.9, 54.1)
Consent sought from 31 (79.5) (64.5, 89.2)
Blinding adequately described 20 (51.3) (36.2, 66.1)
Results Flow diagram provided 24 (61.5) (45.9, 75.1)
Losses and exclusions detailed 30 (76.9) (61.7, 87.4)
Dates of the trial provided 33 (84.6) (70.3, 92.8)
Dates of each time period provided 14 (35.9) (22.7, 51.6)
Baseline data reported 33 (84.6) (70.3, 92.8)
Final number of clusters analyzed detailed 39 (100.0) (91.0, 100.0)
Final number of individuals analyzed detailed 36 (92.3) (29.3, 59.0)
Final number of steps detailed 38 (97.4) (86.8, 99.5)
Summary of outcomes provided 39 (100.0) (91.0, 100.0)
Point estimate and variation estimate of
primary outcome measures provided
32 (82.1) (67.3, 91.0)
Point estimate and variation estimate of
secondary outcome measures provided*
15 (65.2) (44.9, 81.2)
Intention-to-treat analysis used 16 (41.0) (27.1, 56.6)
Intracluster correlation coefficient or
coefficient of variation value reported
6 (15.4) (7.2, 29.7)
Discussion Potential harms detailed 6 (15.4) (7.2, 29.7)
Generalizability of results described 18 (46.2) (31.6, 61.4)
Limitations of the trial described 38 (97.4) (86.8, 99.5)
Interpretation of the results provided 39 (100.0) (91.0, 100.0)
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quality of completed SW-CRCTs. To this end, we
presented a review of 39 completed studies, assessing
their reporting quality through 43 chosen indicators.
Previously conducted reviews on SW-CRCTs have
assessed reporting quality on at most 15 completed
studies and 23 indicators at once. Therefore, we here
provided analysis based on a far larger number of studies
and indicators than previous reviews.
Our analysis found that much work remains to be done
to improve quality. Sound reporting is key to assessing the
Table 3 Quality of reporting of SW-CRCTs (N = 39) (Continued)
Trial registration provided or
referenced
17 (43.6) (29.3, 59.0)
Trial protocol provided or referenced 14 (35.9) (22.7, 51.6)
Trial funding detailed 37 (94.9) (83.1, 98.6)
Overall median – (66.7)
Boldface median (CONSORT) – (80.8)
Italicized median (key) 26 (66.7)
Indicators listed in bold are those contained in the CONSORT extension to CRCTs. Indicators listed in italics are those contained in the chosen subset of 10 key
criteria. The two criteria marked with a * are out of 25 records rather than 39, since secondary outcomes were not present in every trial. An overall median raw
mark, and median raw mark on the CONSORT criteria are consequently not calculable
Fig. 4 Quality of reporting over time. The percentage of the criteria that each study met against its publication year is depicted, according to (a) all
considered criteria, (b) the subset listed on the CONSORT extension to CRCTs, and (c) the 10 criteria chosen as key. A Loess smoother is present on
each graph to indicate time patterns, along with its 95% confidence interval
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validity of a study; however, the median performance across
all considered criteria was 66.7%. Moreover, whilst the type
of randomization used was well described (37/39, 92.3%),
the method of random allocation (23/39, 59.0%), the alloca-
tion concealment mechanism (12/29, 30.8%) and the
person who implemented the randomization (15/39, 38.5%)
was not. Moreover, 25.6% (10/39) of studies did not
describe their designs as randomized in the title or abstract.
Some 15.4% (6/39) of studies successfully detailed any
harm associated with their intervention. In many
instances this may well be because there was no harm,
but it is important to make this clear, particularly as
many of the interventions involve drugs for which side-
effects could well be expected.
In line with a 2016 review [35], 38.5% (15/39) of studies
did not provide any form of justification for their sample
size, and 43.6% (17/39) mentioned the intracluster correl-
ation or coefficient of variation. Moreover, 43.6% (17/39)
and 41.0% (16/39) of the studies did not detail planned
type-I and type-II error rates for their design. Thus, again
there is great room for improvement in the reporting of
the specification of SW-CRCTs.
Nonetheless, from Fig. 4 it does appear somewhat that
the standard of reporting of SW-CRCTs has improved
since 2010. This improvement may be because more has
now been published about the design, or could perhaps
be a result of the lag time for journals adopting the new
criteria contained within the CONSORT extension to
CRCTs [37, 38].
Whilst the median performance across the criteria
listed on the CONSORT extension to CRCTs was 80.8%,
it is more alarming that the mean performance was
70.8%. This, however, should perhaps not surprise us, as
it is not a problem restricted solely to SW-CRCTs.
Indeed several recent reviews have identified that the
reporting of CRCTs in several areas has been poor
[48–51]. In particular, one 2011 review identified that
the quality of reporting of only 5 of 14 considered
criteria had improved following the publication of the
CONSORT extension to CRCTs [51]. However, this
may have been the result of a lag of uptake of the
new criteria. Regardless, further efforts are needed to
improve reporting quality for not only SW-CRCTs,
but all CRCTs. Nonetheless, there are several features
specific to SW-CRCTs not contained within this
CONSORT extension, and therefore further guidance
is needed on publication of SW-CRCTs. Fortunately,
therefore, a CONSORT extension to SW-CRCTs is
now under development [52]. In this extension, it ap-
pears warranted to encourage greater detail on the
timing of each step, to ensure that it is improved in
the future. It will also, in light of recent extensions to
the classical SW-CRCT, be important to define clearly
what constitutes a SW-CRCT, and therefore which
trials would need to adhere to such guidance. Finally,
33.3% (13/39) of trials completed thus far did not
include a diagram of their design. This is strongly
encouraged by the CONSORT extension to CRCTs.
However, it may be wise for it to be listed as a spe-
cific point on an extension to SW-CRCTs, perhaps
even with certain required features, as it is clearly a
very powerful means of detailing a SW-CRCT design.
In addition, we sought to ascertain the general design
features of all SW-CRCTs conducted to date. To this
end, we presented a review of features from an
additional 84 study protocols, registrations and confer-
ence reports, along with those from the aforementioned
39 completed studies.
We observe that 91% of the identified and included
records were from 2010 onwards. Thus, it appears that
the design is increasing in popularity, perhaps reflecting
an increasing acknowledgement of its usefulness, or sim-
ply that more is now known about the design.
It is clear that the design has been used in an
extremely broad range of research areas, in a wide range
of countries. Moreover, the actual characteristics of
the design have varied substantially as well. Therefore,
it seems that the design has proven useful to a large
selection of study scenarios, its benefits seemingly
coming from reasons other than one specific trial sce-
nario. Indeed, our work highlighted once again some
of the advantages of the SW-CRCT design that have
frequently been cited.
We identified that the most common reason for use
was that trial organizers wished to give the intervention
to all clusters eventually. Additionally, a large number
cited logistical and practical constraints that made the
staggered implementation involved in a SW-CRCT
favourable. A small number of studies cited that the
design was preferred for efficiency or power related
reasons. It is, of course, essential to remember that this
is not universally true of the SW-CRCT design. More-
over, some studies cited that the design would allow
them to fine-tune the intervention over time, but it is
important to note that in SW-CRCTs one should not set
out to change the intervention across time periods as
this would imply that the intervention effect would
change during the trial. Overall, however, it seems that
there are a large number of reasons for which the design
has been preferred, contributing to the broad array of
research domains in which it has been utilized.
There are also several disadvantages associated with
the SW-CRCT design [27, 29, 31]. Specifically, if the
chosen SW-CRCT design is one that requires data
collection at each point when a new cluster receives the
experimental intervention, this could, in some circum-
stances, see the cost of data collection become consider-
able. Given that the design is also not guaranteed to
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require a smaller sample size than a parallel group
CRCT, it may also require a substantially longer trial
duration. Consequently, as discussed recently, researchers
must remain careful when deciding whether to employ
the design [29]. This seems particularly true in light of our
findings that 52.0% of completed studies did not find a
significant effect on any primary outcome measure for
which a minimum clinically important difference had been
specified. Of course, it could be that these studies were
simply underpowered, owing to misspecification of the
variance parameters. Extension of the classical SW-CRCT
design to incorporate sample size re-estimation could
therefore be an important advance. Alternatively, to guard
against over-enthusiastic use of the design, interim
analyses to stop the trial early for futility may also be a
useful design extension for trial organizers to consider.
This approach, however, would, of course, not always be
applicable; for example if the intervention were part of
some wider planned roll out, or if the possibility that some
clusters might not receive the intervention was deemed
unacceptable.
Strengths and limitations
We used a literature search strategy based on a previ-
ously completed review to identify relevant articles for
inclusion. In particular, we utilized a large number of
search terms, across a large number of databases, and
set no limits on the publication date. Therefore, we were
able to complete an assessment of the general design
features and quality of reporting of SW-CRCTs to date
on more trials than all previous reviews. However, it is
still possible that some studies might have been missed
that used other phrases to describe their design that we
did not include in our search. Additionally, we might
have missed some studies reporting in languages other
than English. Finally, several reviews, ours included, have
now looked to include SW-CRCTs conducted in non-
health based research settings. However, to maximize
the chance of such studies being identified, additional
databases should be included, such as the Campbell
Collaboration [53].
We chose to exclude studies where there was no
(baseline) period present in which no clusters received
the experimental intervention; however, following recent
publications many might consider designs of this form
as SW-CRCTs. Moreover, similar statements are true for
incomplete block SW-CRCTs. Future researchers might
seek to include such studies in their reviews. Further-
more, we chose to assess reporting quality on a particu-
lar set of 10 criteria, which we chose to be key. Whilst
justification for our choices was discussed, some
researchers might have preferred alternate criteria to be
included in this list. It is possible that future work could
convene a panel of experts on SW-CRCT designs to
determine which criteria to view as of paramount im-
portance, enlisting the help, for example, of the Comet
Initiative [54] or the Equator Network [55].
In addition, future reviews could seek to expand the
classification of their extracted data beyond our, and the
previous reviewers’, simple ‘yes or no’ prescription. For
some of the considered criteria, it would be particularly
beneficial to incorporate whether they were partially
satisfied, according to some designated scoring procedure.
This would potentially allow the improvement of the
reporting of SW-CRCTs to be more accurately measured.
Finally, only one author conducted the inclusion
search and the eventual data extraction. In our initial
planning of the review, we did consider the use of dupli-
cate abstract screening and data extraction. However, it
was decided one author would perform all of the screen-
ing and data extraction, marking the cases where deci-
sions were unclear for joint discussion with the other
authors. This was because, in nearly all cases, it was very
clear what decision should be made, with this fact
assisted by the careful choice of criteria that avoided the
need for any subjective opinion. We acknowledge that
this deviates from best practice for conducting a review
but are confident it has not affected the quality of our
work. For record selection, this claim is backed up by
the verification that all trials included in previous
reviews, that met our choice of inclusion criteria, were
included in our review.
Conclusions
We identified that regardless of evidence of recent
improvements, the quality of reporting of SW-CRCTs
has been low. There is therefore a need for further guid-
ance on how to report such trials, and the CONSORT
extension to SW-CRCTs, currently under development,
certainly seems warranted. Through this, precisely which
information should be included when presenting the
results of a SW-CRCT, and what constitutes a
SW-CRCT, should be clarified, such that future SW-
CRCTs may be better reported.
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